2026³â 05¿ù 07ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research

´º½ºÀÏÀÚ: 2025-06-19

SYDNEY -- Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions.

The Next Frontier explores how biotechnology is addressing some of the world’s most urgent health and sustainability challenges. As part of the series, Novotech highlights its partnership with Tune Therapeutics in advancing a functional cure for Hepatitis B, a chronic disease impacting nearly 300 million people globally. As the global leader in Hepatitis clinical trials, Novotech brings deep therapeutic expertise and global execution capabilities to accelerate development and delivery for sponsors.

Filmed in New Zealand with world-leading hepatologist Professor Edward Gane, where an estimated 100,000 people are living with Hepatitis B, the feature highlights Novotech’s partnership model for supporting biotech and small to mid-size pharma sponsors. It demonstrates how Novotech accelerates clinical development through access to expert investigators, targeted patient populations, and efficient trial infrastructure across Asia-Pacific, Europe, and North America, while showcasing its global capabilities in infectious disease research and trial delivery.

“Our inclusion in this series reflects Novotech’s commitment to supporting innovators with smarter, faster, and more regionally tailored clinical solutions,” said Tom Hickey, Director of Therapeutic Strategy. “Hepatitis B remains a significant global health challenge, and our teams are proud to have such a long history contributing to meaningful progress in this area.”



 Àüü´º½º¸ñ·ÏÀ¸·Î

Quectel Expands Small Cell Antennas Portfolio With Five New Products
Mainland China Cloud Infrastructure Spending Rises 26% in Q4 2025, Driven by AI and Agent Growth
Quectel Introduces FGH200M Wi-Fi HaLow Module for massive IoT Deployments
AMOLED Smartphone Display Shipments Expected to Decline Sharply in 2026
Axelspace-Led Consortium Chosen for Japan Space Fund Project on Next-Gen Earth Observation Satellite Technology
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering

 

Boomi Builds Analyst Momentum Across Integration, API Management, Data...
Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 ...
Takeda¡¯s Zasocitinib Shows Rapid, Durable Skin Clearance in Once-Dail...
Regnology Announces Next-Generation Ascend Platform with Agentic AI, A...
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation
AI Ambitions at Risk as Only 14% of Enterprises Fully Realize Cloud Va...
Boomi Named a Leader in IDC MarketScape for Worldwide API Management 2...

 


°øÁö»çÇ×
'º£³×ÀÍ' Áß¹® Ç¥±â 宝Ò¬ìÌ, 'À̺ñÁî: ÀÌÁö' Áß¹® Ç¥±â æ¶币òª...
¿¡³ÊÀ¯ Enereu 额Òö äþÒö
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ºÁö'
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®À¯ºñ Alliuv ä¹备: ä¹êó备, ¾Ë¶ã Althle ä¹÷åìÌ
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØ ä¹ì³ÜØ
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..